A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Stopped The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns

Conditions

• Carcinoma, Non Small Cell Lung
• Carcinoma, Pancreatic Ductal
• Malignant Melanoma
• Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions

• DRUG: PF-08046037
• DRUG: sasanlimab

Sponsor

Pfizer